Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 6/20 | 0.48 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.36 |
| ▸ | MMP1 known ✓ | P03956 | 10/20 | 0.32 |
| ▸ | MMP8 known ✓ | P22894 | 4/20 | 0.32 |
| ▸ | MMP13 known ✓ | P45452 | 3/20 | 0.32 |
| ▸ | MMP7 known ✓ | P09237 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 9/20 | 0.32 |
| ▸ | MMP2 | P08253 | 8/20 | 0.32 |
| ▸ | MMP9 | P14780 | 7/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.31 |
| ▸ | MMP14 | P50281 | 2/20 | 0.31 |
| ▸ | TNF | P01375 | 2/20 | 0.31 |
| ▸ | MMP20 | O60882 | 1/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.31 |
| ▸ | MMP10 | P09238 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP15 | P51511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2005458 | 1.00 | DPP4 (0.48) | DPP4ALDH1A1MAPTPTGS1CIT | |
| Hydrochloric Acid SCHEMBL20721188 | 1.00 | DPP4 (0.48) | DPP4ALDH1A1MAPTPTGS1CIT | |
| SCHEMBL342534 | 0.97 | DPP4 (0.50) | DPP4ALDH1A1MAPTPTGS1CIT | |
| SCHEMBL1174655 | 0.97 | DPP4 (0.50) | DPP4ALDH1A1MAPTPTGS1CIT | |
| SCHEMBL343358 | 0.97 | DPP4 (0.50) | DPP4ALDH1A1MAPTPTGS1CIT | |
| Trifluoroacetic Acid SCHEMBL7399856 | 0.85 | DPP4 (0.42) | DPP4ALDH1A1MAPTPTGS1CIT | |
| Hydrochloric Acid SCHEMBL1174259 | 0.81 | DPP4 (0.33) | DPP4ALDH1A1MAPTPTGS1FAP | |
| SCHEMBL3416457 | 0.80 | SPHK1 (0.41) | DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL14261061 | 0.78 | DPP4 (0.47) | DPP4ALDH1A1MAPTPTGS1CIT | |
| SCHEMBL8202933 | 0.78 | MAPT (0.34) | DPP4ALDH1A1MAPTPTGS1FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250214928-A1 | Process for the preparation of marimastat, marimastat prepared by this process, a pharmaceutical composition comprising the same, and uses thereof | PIKRALIDA SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2025-07-03 | — | — | US | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-0923585-B1 | PHOSPHINATE BASED INHIBITORS OF MATRIX METALLOPROTEASES | PFIZER (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6147061-A | ANTIARTHRITIC AGENTS; ANTICANCER AGENTS; ORAL DISEASES | PFIZER INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0976721-A2 | Process for the preparation of amino acids and amino acid derivatives | Degussa-Hüls Aktiengesellschaft (DE) | 2000-02-02 | — | — | EP | disclosed |
| US-5618844-A | MATRIX METALLOPROTEINASE INHIBITOR | SANOFI S.A. (FR) | 1997-04-08 | — | — | US | disclosed |
| US-5514716-A | MATRIX METALLOPROTEINASE INHIBITORS, ANTIARTHRITIC | STERLING WINTHROP, INC. (US) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214928-A1 | Process for the preparation of marimastat, marimastat prepared by this process, a pharmaceutical composition comprising the same, and uses thereof | MMP7, MMP9, MMP3 | DPP4 463/4885PTGS1 2400/4885MMP1 7/4885 |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | DPP4 2375/4885PTGS1 191/4885MMP1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.